Li Li, Miyamoto Masaki, Ebihara Yuma, Mega Seiji, Takahashi Ryo, Hase Ryunosuke, Kaneko Hiroyuki, Kadoya Masatoshi, Itoh Tomoo, Shichinohe Toshiaki, Hirano Satoshi, Kondo Satoshi
Department of Surgical Oncology, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, N15W7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.
World J Surg. 2006 Sep;30(9):1672-9; discussion 1680-1. doi: 10.1007/s00268-006-0035-3.
Dopamine receptors (DRs) are members of seven transmembrane domain trimeric guanosine 5'-triphosphate (GTP)-binding protein-coupled receptor family. Through dopamine receptor activation, dopamine plays a significant role in regulating gene expression, such as induced tumor cell migration.
We investigated DRD1 and DRD2 expressions in patients with esophageal squamous cell carcinoma (ESCC) for immunohistochemistry and analyzed differences between DRD1, DRD2, and DARPP-32 expressions of clinicopathological features in 122 patients with ESCC.
DRD1 immunostaining correlated with the pathologic grade (P = 0.0127), and DRD2 immunostaining correlated with the pathologic stage (P = 0.0432) and pN classification (P = 0.0112). A significant correlation was found between DRD1 and DRD2 expression (P = 0.0292). However, no correlation was observed between DRD1/DRD2 expression and DARPP-32 expression (P = 0.4555 and 0.4774, respectively). No correlation was observed between the DRD1/DRD2 expression and patient prognosis. To find the cooperative role between DRD1, DRD2, and DARPP-32 expressions, patients were classified into the different groups. In the DRD2/DARPP-32 combination, the (+/-) group was significantly correlated with pathologic stage (P = 0.0006), lymph node metastasis (P = 0.0001), pT (P = 0.0287), and tumor size (P = 0.0202). Moreover, patients with this combination showed a lower survival rate compared with the other three groups (P = 0.0287).
We conclude that DRD2/DARPP-32 expression is associated with tumor progression and that DRD2/DARPP-32 expressions may help predict prognosis in patients with ESCC.
多巴胺受体（DRs）是七跨膜结构域三聚体鸟苷5'-三磷酸（GTP）结合蛋白偶联受体家族的成员。通过多巴胺受体激活，多巴胺在调节基因表达中发挥重要作用，如诱导肿瘤细胞迁移。
我们采用免疫组织化学方法研究了食管鳞状细胞癌（ESCC）患者中DRD1和DRD2的表达情况，并分析了122例ESCC患者的临床病理特征中DRD1、DRD2和DARPP-32表达之间的差异。
DRD1免疫染色与病理分级相关（P = 0.0127），DRD2免疫染色与病理分期（P = 0.0432）和pN分类相关（P = 0.0112）。DRD1和DRD2表达之间存在显著相关性（P = 0.0292）。然而，未观察到DRD1/DRD2表达与DARPP-32表达之间的相关性（分别为P = 0.4555和0.4774）。未观察到DRD1/DRD2表达与患者预后之间的相关性。为了探究DRD1、DRD2和DARPP-32表达之间的协同作用，将患者分为不同组。在DRD2/DARPP-32组合中，（+/-）组与病理分期（P = 0.0006）、淋巴结转移（P = 0.0001）、pT（P = 0.0287）和肿瘤大小（P = 0.0202）显著相关。此外，与其他三组相比，该组合的患者生存率较低（P = 0.0287）。
我们得出结论，DRD2/DARPP-32表达与肿瘤进展相关，且DRD2/DARPP-32表达可能有助于预测ESCC患者的预后。
